APRI - Apricus Biosciences, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.79
+0.01 (+0.56%)
At close: 3:58PM EDT

1.82 +0.03 (1.68%)
After hours: 4:01PM EDT

Stock chart is not supported by your current browser
Previous Close1.78
Open1.76
Bid1.68 x 100
Ask1.98 x 1000
Day's Range1.75 - 1.87
52 Week Range0.26 - 4.07
Volume184,144
Avg. Volume382,796
Market Cap22.88M
Beta-0.74
PE Ratio (TTM)2.99
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Should You Be Concerned About Apricus Biosciences Inc’s (APRI) Risks?
    Simply Wall St.7 days ago

    Should You Be Concerned About Apricus Biosciences Inc’s (APRI) Risks?

    For Apricus Biosciences Inc’s (NASDAQ:APRI) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock inRead More...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of APRI earnings conference call or presentation 2-Aug-17 8:30pm GMT

    Q2 2017 Apricus Biosciences Inc Earnings Call

  • Capital Cube2 months ago

    ETFs with exposure to Apricus Biosciences, Inc. : August 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Apricus Biosciences, Inc. Here are 5 ETFs with the largest exposure to APRI-US. Comparing the performance and risk of Apricus Biosciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Associated Press2 months ago

    Apricus reports 2Q loss

    The San Diego-based company said it had a loss of 13 cents per share. Losses, adjusted to account for discontinued operations, came to 15 cents per share. In the final minutes of trading on Wednesday, ...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of APRI earnings conference call or presentation 11-May-17 8:30pm GMT

    Q1 2017 Apricus Biosciences Inc Earnings Call

  • Associated Press5 months ago

    Apricus posts 1Q profit

    On a per-share basis, the San Diego-based company said it had net income of $1.04. Losses, adjusted to account for discontinued operations, were 44 cents per share. In the final minutes of trading on Thursday, ...

  • Capital Cube6 months ago

    ETFs with exposure to Apricus Biosciences, Inc. : April 19, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Apricus Biosciences, Inc. Here are 5 ETFs with the largest exposure to APRI-US. Comparing the performance and risk of Apricus Biosciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube6 months ago

    ETFs with exposure to Apricus Biosciences, Inc. : April 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Apricus Biosciences, Inc. Here are 5 ETFs with the largest exposure to APRI-US. Comparing the performance and risk of Apricus Biosciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Apricus Biosciences, Inc. :APRI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
    Capital Cube7 months ago

    Apricus Biosciences, Inc. :APRI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis Apricus Biosciences, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Apricus Biosciences, Inc. – VIVUS, Inc., Pfizer Inc., Bioanalytical Systems, Inc., Abbott Laboratories, Eli Lilly and Company, Ligand Pharmaceuticals Incorporated and Novartis AG Sponsored ADR (VVUS-US, PFE-US, BASI-US, ... Read more (Read more...)

  • Associated Press7 months ago

    Apricus reports 4Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 4 cents. The drugmaker posted revenue of $400,000 in the period. For the year, the company reported that its loss narrowed to $7.4 ...

  • Investopedia7 months ago

    Apricus Biosciences Sells ED Therapy Rights

    Apricus will receive $12.7 million from the sale of its erectile dysfunction therapy Vitaros to Ferring.

  • 24/7 Wall St.9 months ago

    Thursday’s Top Biopharma Movers

    Not that many biotech and pharma companies were on the move Thursday, just one day before the inauguration. However, a few of the smaller caps made splash.

  • Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico
    Zacks9 months ago

    Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico

    Apricus (APRI) announced that Vitaros was approved in Mexico for the treatment of patients with erectile dysfunction.

  • 24/7 Wall St.9 months ago

    How Erectile Dysfunction in Mexico Just Made One Micro-Cap Stock More Than Double

    The biotechs and emerging pharma have been under pressure from politicians attacking drug prices. That doesn't mean that there are not some big winners out there.

  • 24/7 Wall St.9 months ago

    Wednesday’s Top Biopharma Winners

    Trump said last week that companies in the health care sector are “getting away with murder,” and that something had to change. The sector has pulled back slightly since then, but there are still companies ...

  • Apricus Launches Vitaros in Lebanon for Erectile Dysfunction
    Zacks10 months ago

    Apricus Launches Vitaros in Lebanon for Erectile Dysfunction

    Apricus Biosciences, Inc. (APRI) announced that its topical cream, Vitaros for the treatment of erectile dysfunction (ED) has been launched in Lebanon by partner Elis Pharmaceuticals Ltd.

  • Capital Cube10 months ago

    ETFs with exposure to Apricus Biosciences, Inc. : December 13, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Apricus Biosciences, Inc. Here are 5 ETFs with the largest exposure to APRI-US. Comparing the performance and risk of Apricus Biosciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Zacks10 months ago

    Zacks.com featured highlights: Baxter International, MAM Software Group, Advanced Energy Industries, Apricus Biosciences and Copart

    Zacks.com featured highlights: Baxter International, MAM Software Group, Advanced Energy Industries, Apricus Biosciences and Copart

  • Zacks10 months ago

    5 Efficient Stocks to Buy for Superlative Returns

    Investors seeking impressive returns irrespective of market conditions may consider adding stocks with favorable efficiency levels to their portfolios.

  • Apricus Biosciences Aims to Resubmit Vitaros NDA in 2017
    Zacks11 months ago

    Apricus Biosciences Aims to Resubmit Vitaros NDA in 2017

    Apricus Biosciences, Inc. (APRI) announced that it intends to resubmit its new drug application (NDA) for its drug Vitaros in 2017.

  • Capital Cube11 months ago

    ETFs with exposure to Apricus Biosciences, Inc. : November 16, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Apricus Biosciences, Inc. Here are 5 ETFs with the largest exposure to APRI-US. Comparing the performance and risk of Apricus Biosciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Thomson Reuters StreetEvents11 months ago

    Edited Transcript of APRI earnings conference call or presentation 8-Nov-16 9:30pm GMT

    Q3 2016 Apricus Biosciences Inc Earnings Call

  • Here Are Two Biotechs That Are Down But Could Recover Near Term
    Insider Monkeylast year

    Here Are Two Biotechs That Are Down But Could Recover Near Term

    Yet again, it’s been a busy start to the week in biotech. A couple of companies have picked up early week gains, but more have suffered, and some considerably. Here are two companies that have struggled so far this week, but might recover medium term. We’ll kick things off with Aduro BioTech Inc (NASDAQ:ADRO). Aduro […]